4.8 Article

The ubiquitin-specific protease USP47 is a novel β-TRCP interactor regulating cell survival

Journal

ONCOGENE
Volume 29, Issue 9, Pages 1384-1393

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.430

Keywords

ubiquitin; F-box proteins; beta-Trcp; degradation

Funding

  1. EU [LSHB-CT-019067]
  2. Alleanza contro il Cancro [ACC12/6]
  3. MIUR/PRIN [RBIP06LCA9_0023]
  4. AIRC [2008-2010_33-08]
  5. ISS 'Program Italia-USA' [N526D5]
  6. Italian Human ProteomeNet [RBRN07BMCT_007]
  7. Telethon
  8. National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]
  9. Multiple Myeloma Research Foundation
  10. Philip Morris USA Inc.
  11. Philip Morris International
  12. American Cancer Society
  13. MRC [MC_U132670600] Funding Source: UKRI
  14. Medical Research Council [MC_U132670600] Funding Source: researchfish

Ask authors/readers for more resources

Ubiquitin-specific proteases (USPs) are a subclass of cysteine proteases that catalyze the removal of ubiquitin (either monomeric or chains) from substrates, thus counteracting the activity of E3 ubiquitin ligases. Although the importance of USPs in a multitude of processes, from hereditary cancer to neurodegeneration, is well established, our knowledge on their mode of regulation, substrate specificity and biological function is quite limited. In this study we identify USP47 as a novel interactor of the E3 ubiquitin ligase, Skp1/Cul1/F-box protein beta-transducin repeat-containing protein (SCF beta-Trcp). We found that both beta-Trcp1 and beta-Trcp2 bind specifically to USP47, and point mutations in the beta-Trcp WD-repeat region completely abolished USP47 binding, indicating an E3-substrate-type interaction. However, unlike canonical beta-Trcp substrates, USP47 protein levels were neither affected by silencing of beta-Trcp nor modulated in a variety of processes, such as cell-cycle progression, DNA damage checkpoint responses or tumor necrosis factor (TNF) pathway activation. Notably, genetic or siRNA-mediated depletion of USP47 induced accumulation of Cdc25A, decreased cell survival and augmented the cytotoxic effects of anticancer drugs. In conclusion, we showed that USP47, a novel beta-Trcp interactor, regulates cell growth and survival, potentially providing a novel target for anticancer therapies. Oncogene (2010) 29, 1384-1393; doi:10.1038/onc.2009.430; published online 7 December 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available